WallStreetZenWallStreetZen

NASDAQ: MYGN
Myriad Genetics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Myriad Genetics revenue was $823.60M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2024) ending on Sep 30, 2024 was $213.3M, up 0.9% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, MYGN annual revenue was $753.2M, with 11% growth year-over-year.

MYGN past revenue growth

How has MYGN's revenue growth performed historically?

Company
12.15%
Industry
1.55%
Market
33.79%
MYGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MYGN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MYGN's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

MYGN revenue history

Current Revenue
$823.6M
Current Earnings
-$116.0M
Current Profit Margin
-14.1%

Be the first to know when MYGN announces revenue.

MYGN Revenue History By Year

MYGN Yearly RevenueMYGN RevenueMYGN ChangeMYGN Revenue Growth
2023-12-31$753.20M$74.80M+11.03%
2022-12-31$678.40M-$12.20M-1.77%
2021-12-31$690.60M$52.00M+8.14%
2020-06-30$638.60M-$212.50M-24.97%
2019-06-30$851.10M$107.40M+14.44%
2018-06-30$743.70M$15.00M+2.06%
2017-06-30$728.70M-$11.80M-1.59%
2016-06-30$740.50M$17.40M+2.41%
2015-06-30$723.10M-$55.10M-7.08%
2014-06-30$778.20M$165.00M+26.91%
2013-06-30$613.20M$117.20M+23.63%
2012-06-30$496.01M$93.92M+23.36%
2011-06-30$402.08M$39.44M+10.87%
2010-06-30$362.65M$36.12M+11.06%
2009-06-30$326.53M$103.67M+46.52%
2008-06-30$222.86M$77.57M+53.39%
2007-06-30$145.29M$31.01M+27.13%
2006-06-30$114.28M$31.87M+38.68%
2005-06-30$82.41M$25.76M+45.47%
2004-06-30$56.65M-$7.67M-11.93%
2003-06-30$64.32M$10.49M+19.48%
2002-06-30$53.84M$8.67M+19.21%
2001-06-30$45.16M$11.15M+32.78%
2000-06-30$34.01M$8.70M+34.37%
1999-06-30$25.31M$2.10M+9.06%
1998-06-30$23.21M$7.97M+52.34%
1997-06-30$15.24M$8.61M+129.85%
1996-06-30$6.63M$5.33M+412.06%
1995-06-30$1.29MN/AN/A

1 of 2

Myriad Genetics Revenue FAQ

What was MYGN's revenue last quarter?

On Invalid Date, Myriad Genetics (NASDAQ: MYGN) reported Q3 2024 revenue of $213.30 million up 11.15% year over year. In the same quarter last year, Myriad Genetics's revenue was $191.90 million.

What was Myriad Genetics's revenue in 2023?

Myriad Genetics's annual revenue for the twelve months ending Dec 31, 2023 was $753.20 million, a 11.03% increase year over year.

How much does Myriad Genetics make in a day?

Based on Myriad Genetics annual revenue for the past five years, MYGN makes an average of $1,979,123.29 per day.

What was Myriad Genetics's annual revenue growth in the past year?

As of Q1 2025, Myriad Genetics's revenue has grown 12.15% year over year. This is 10.6 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 1.55%. Myriad Genetics's revenue in the past year totaled $823.60 million.

How much does Myriad Genetics make in a year?

Myriad Genetics's revenue by year for the past five years is:
  • Myriad Genetics's revenue for the twelve months ending Dec 31, 2023 was $753.20 million, a 11.03% increase year over year.
  • Myriad Genetics's annual revenue for Dec 31, 2022 was $678.40 million, a 1.77% decrease from 2021.
  • Myriad Genetics's annual revenue for 2021 was $690.60 million, a 8.14% increase from 2020.
  • Myriad Genetics's annual revenue for 2020 was $638.60 million, a 24.97% decrease from 2019.
  • Myriad Genetics's annual revenue for 2019 was $851.10 million, a 14.44% increase from 2018.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.